

May 26, 2022

National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th Floor, Plot No: C/1, G - Block, Bandra- Kurla Complex, Bandra (East), Mumbai - 400 051 NSE Symbol: ORCHPHARMA	BSE Limited Corporate Relationship Department 1st floor, New Trading Ring, Rotunda Building, P J Towers, Dalal Street, Fort Dalal Street, Fort Bandra (East), Mumbai - 400 051 BSE Code: 524372
--	--

Dear Sir/Madam

Subject: Disclosure under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the disclosure on Related Party Transactions, on a consolidated basis, prepared in accordance with the applicable accounting standards for the half year ended March 31, 2022.

This disclosure will also be made available on the website of the Company and can be accessed using the link http://www.orchidpharma.com/invr_intimation.aspx

Kindly take the above information on records.

Thanking you,

Yours faithfully,

For **Orchid Pharma Limited**

Orchid Pharma Limited

Disclosure of related party transactions for the half year ended March 31,2022

(Amount Rs. in Lakhs)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S. No.	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
		Name	Name				Relationship of the counterparty with the listed entity or its subsidiary	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/Unsecured
1	Orchid Pharma Limited	Dhanuka Laboratories Limited	Holding Company	Purchase of goods	2400	1220.54	6.23	-	-	-	-	-	-	-	-	-
2	Orchid Pharma Limited	Dhanuka Laboratories Limited	Holding Company	Advance towards purchase of land	2696	674.03	-	674.03	-	-	-	-	-	-	-	-
3	Orchid Pharma Limited	Otsuka Chemical(India) Private Limited	Related Party under Section 2(76)(iv) of the Companies Act,2013	Purchase of goods	7500	4936.47	-	3,472.27	-	-	-	-	-	-	-	-
4	Orchid Pharma Limited	Synmedic Laboratories	Related Party under Section 2(76)(iii) of the Companies Act,2013	Sale of goods	1500	167.01	-	-	-	-	-	-	-	-	-	-
5	Orchid Pharma Limited	Synmedic Laboratories	Related Party under Section 2(76)(iii) of the Companies Act,2013	Advance towards purchase of land	1971	492.90	-	492.90	-	-	-	-	-	-	-	-
6	Orchid Pharma Limited	OrBion Pharmaceuticals Private Limited	Associate Company	Sale of Product/Services	200	5.29	-	-	-	-	-	-	-	-	-	-
7	Orchid Pharma Limited	Orchid Pharma Inc	Subsidiary Company	Trade receivables	-	-	4,148.26	3,839.28	-	-	-	-	-	-	-	-
8	Orchid Pharma Limited	OrBion Pharmaceuticals Private Limited	Associate Company	Trade receivables (Does not include working capital adjustments)	-	-	-	5.29	-	-	-	-	-	-	-	-
9	Orchid Pharma Limited	Orchid Europe Limited	Subsidiary Company	Trade payable	-	-	31.12	31.12	-	-	-	-	-	-	-	-
10	Orchid Pharma Limited	Shri Manish Dhanuka	Managing Director	Remuneration and short term benefits to Key Management Personnel (Managing Director, Whole Time Director and Company Secretary)#	As approved by the NRC and Board and as per the Remuneration policy	37.53	-	-	-	-	-	-	-	-	-	-
		Shri Mridul Dhanuka	Wholetime Director			37.53	-	-	-	-	-	-	-	-	-	
		Ms. Nikita K	Company Secretary			4.21	-	-	-	-	-	-	-	-	-	
11	Orchid Pharma Limited	Shri Ram Gopal Agarwal	Non-Executive Director	Sitting fee to Non-Executive Directors	As approved by the NRC and Board	0.25	-	-	-	-	-	-	-	-	-	-
12	Orchid Pharma Limited	Shri Arun Kumar Dhanuka	Non-Executive Director	Sitting fee to Non-Executive Directors		0.75	-	-	-	-	-	-	-	-	-	-
13	Orchid Pharma Limited	Dr. Dharam Vir	Independent Director	Sitting fee to Non-Executive Directors		1.1	-	-	-	-	-	-	-	-	-	-
14	Orchid Pharma Limited	Shri Manoj Kumar Goyal	Independent Director	Sitting fee to Non-Executive Directors		1.25	-	-	-	-	-	-	-	-	-	-
15	Orchid Pharma Limited	Shri Mudit tandon	Independent Director	Sitting fee to Non-Executive Directors		0.80	-	-	-	-	-	-	-	-	-	-
16	Orchid Pharma Limited	SHR. SANU Singla	Independent Director	Sitting fee to Non-Executive Directors		1.25	-	-	-	-	-	-	-	-	-	-

No remuneration was paid to Shri Sunil Kumar Gupta, Chief Financial Officer during the period October 01,2021-March 31,2022

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year-end are unsecured and interest fee and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. A provision has been created for invoices raised from financial year 2017-2018 till date. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

Sunil Kumar Gupta
Chief Financial Officer